Dr. Lal PathLabs Limited share price
NSE: LALPATHLAB · ISIN INE600L01024
Key numbers
- Market cap
- ₹ 32,599 Cr
- Current price
- ₹ 1,952.30
- 52-week high / low
- ₹ 2,039 / 1,273
- Stock P/E
- 60.2
- Book value
- ₹ 150.2
- Dividend yield
- 1.02%
- ROCE
- 27.5%
- ROE
- 21.6%
- Debt to equity
- 0.08
- Sales growth (3 yrs)
- 11.1%
- Profit growth (3 yrs)
- 28.3%
- 1-year return
- 18.2%
About Dr. Lal PathLabs Limited
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 603 | 670 | 660 | 703 | 798 |
| Operating profit | 247 | 192 | 179 | 287 | 248 |
| Net profit | 155 | 132 | 91 | 131 | 170 |
| EPS (₹) | - | 7.94 | 5.42 | 7.86 | 10.15 |
Concall summary (2026-07-30)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- 798 crore in Q1 FY27, registering a year-on-year growth of 19.1%.
- 192 crore in Q1 FY26, with a growth of 28.7%, with EBITDA margin of 31.0%. • Profit before tax rose to Rs.
Growth & demand
- The revenue growth is mainly driven by Patient volumes which stood at 8.2 million with a growth of 8.2% and sample volumes which stood at 25.9 million with a growth of 10.7%.
- And in terms of volume growth, this is second quarter we have maintained 8% volume growth, once a slightly softer quarter.
Margins & costs
- 181 crore, up 26.3%, with a PBT margin of 28.7%. • Profit after tax stood at Rs.
- There are costs related to logistics & courier which has been reclassified from manpower personal cost to other logistics cost, which is part of other costs.
Capex & expansion
- In parallel, the broader healthcare ecosystem is expanding, with hospitals across the country adding new capacity and capability.
- Lal PathLabs is well placed to lead through this shift, and our continued investment in scientific leadership, R&D, digital infrastructure and service standards, is aimed squarely at capturing it responsibly for the long term.
Balance sheet & cash
- We continue to leverage our Digital Infrastructure & AI tools to improve customer experience, optimize operations, and advance clinic al capabilities in areas such as histopathology and cancer diagnostics.
- 7.9 in the corresponding quarter last year. • Our balance sheet continues to be strong and resilient, with net cash and equivalents of Rs.
Peers in Diagnostics & Research
Data for information only, not investment advice. Prices end of day.